Search clinical trials for: Obinutuzumab

Total 312 results

1
2
3
4
5
6
7
›

Institute of Hematology & Blood Diseases Hospital...

Recruiting

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

Marginal Zone Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Treatment

China
Liling Zhang

Not yet recruiting

Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden (GLOHRT-01)

Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Qianfoshan Hospital

Not yet recruiting

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy
Michael Choi
Pharmacyclics LLC.

Withdrawn

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Chronic Lymphocytic Leukemia
Huai'an First People's Hospital

Recruiting

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Marginal Zone Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia (2023CD20ITP)

Immune Thrombocytopenia | Treatment

China
Hoffmann-La Roche

Completed

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Follicular Lymphoma | Chronic Lymphocytic Leukemia

Korea, Republic of
French Innovative Leukemia Organisation
Hoffmann-La Roche

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)

Richter Syndrome

France
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

Obinutuzumab | Rapid Infusion | Intravenous Infusion Reaction

China
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi (FIL_GAZEBO)

Follicular Lymphoma

Italy
Paolo Ghia

Recruiting

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (FIGHT)

Chronic Lymphocytic Leukemia

Italy
Polish Myeloma Consortium
Roche Pharma AG; Bioscience, S.A.

Unknown

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 (OBI-1)

Waldenstrom Macroglobulinemia

Poland
TG Therapeutics, Inc.

Completed

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
University of Ulm
AbbVie; Roche Pharma AG; Janssen-Cilag Ltd.; German CLL Study Group

Completed

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (CLL2-GiVe)

Leukemia, Lymphocytic, Chronic

Germany
Heidelberg University
Roche Pharma AG

Active, not recruiting

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Stage II Grade 1 Follicular Lymphoma | Stage II Grade 2 Follicular Lymphoma | Stage I Follicular Lymphoma Grade 1 | Stage II Follicular Lymphoma Grade 2

Germany
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
Ruijin Hospital

Not yet recruiting

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Marginal Zone Lymphoma(MZL)
The First Affiliated Hospital of Xiamen University
Sun Yat-sen University; Fujian Cancer Hospital; Huazhong University of Science... and other collaborators

Recruiting

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Follicular Lymphoma | Newly Diagnosed

China
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
Nantes University Hospital
Roche Pharma AG; Janssen, LP

Active, not recruiting

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (OAsIs)

Mantle Cell Lymphoma

France, United Kingdom
Mayo Clinic
Genentech, Inc.

Active, not recruiting

Obinutuzumab in Primary FSGS

Primary Focal Segmental Glomerulosclerosis

United States
Deok-Hwan Yang
Roche Pharma AG

Unknown

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Chronic Lymphocytic Leukemia

Korea, Republic of
Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

United States
Menarini Group

Terminated

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET)

Tumor Lysis Syndrome

Spain, Hungary, Italy, Bulgaria
Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Spain
Assistance Publique - Hôpitaux de Paris

Recruiting

Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome (OBIRINS)

Steroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic Syndrome

France
Affiliated Hospital of Nantong University

Not yet recruiting

Obinutuzumab in Chinese Real-world Patients With iNHL

Lymphomas Non-Hodgkin's B-Cell

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis (OBI-WAN)

Granulomatosis With Polyangiitis

France
Hoffmann-La Roche

Completed

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) (URBAN)

Follicular Lymphoma

Italy
Ruijin Hospital

Not yet recruiting

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Diffuse Large B Cell Lymphoma (DLBCL)

China
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
University of California, San Diego
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Chronic Lymphocytic Leukemia

United States
Genentech, Inc.

Completed

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Lymphocytic Leukemia, Chronic

United States
Hoffmann-La Roche

Completed

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

China
Chugai Pharmaceutical

Recruiting

A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

Solid Tumor

United States, Japan
Case Comprehensive Cancer Center
Genentech, Inc.

Withdrawn

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder | PTLD
Peking Union Medical College Hospital

Recruiting

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Marginal Zone Lymphoma

China
Johannes Gutenberg University Mainz
Roche Pharma AG; Servier

Completed

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Lymphoma, Non-Hodgkin

Germany
Zulfa Omer
Newave Pharmaceutical Inc

Not yet recruiting

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL/SLL | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
AbbVie

Active, not recruiting

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (453 Ph1 CLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Germany, Israel, Italy
Hoffmann-La Roche

Completed

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Metastatic Colorectal Cancer

Spain, Denmark, Korea, Republic of, United Kingdom, Netherlands
Celgene

Completed

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma, Non-Hodgkin

Canada, Spain, United States, Austria
Hoffmann-La Roche

Completed

A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Lymphoma

France, Germany
Ruijin Hospital

Not yet recruiting

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Mantle Cell Lymphoma
Polish Lymphoma Research Group
Roche Pharma AG

Terminated

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse (OPERA-PLRG10)

Mantle Cell Lymphoma

Poland
Klinikum Stuttgart
University Hospital Freiburg

Terminated

Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (VENOBI-CNS)

Primary CNS Lymphoma

Germany
Hoffmann-La Roche

Completed

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Solid Tumors

United States, Denmark, Spain, Canada, France, Netherlands, Italy

1
2
3
4
5
6
7
›

3

Subscribe